Status: Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
Participants needed: 60
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Fujian Shengdi Pharmaceutical Co., Ltd.Updated: Aug 12, 2025Locations: 1
Eligibility criteria
Males or infertile women aged 18-65 years (inclusive); [+2]
Abnormal daily life rhythm; [+6]